VIVACAINE Drug Patent Profile

Which patents cover Vivacaine, and what generic alternatives are available?

Vivacaine is a drug marketed by Septodont and is included in one NDA.

The generic ingredient in VIVACAINE is bupivacaine hydrochloride; epinephrine bitartrate. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride; epinephrine bitartrate profile page.

Summary for VIVACAINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VIVACAINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont	VIVACAINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	077250-001	Sep 27, 2006		RX	No	Yes

Last updated: July 27, 2026

Vivacaine (bupivacaine) investment scenario and patent/regulatory fundamentals analysis

Vivacaine is a brand name for bupivacaine hydrochloride (local anesthetic). The investment picture is driven by (1) patent and Orange Book status for specific Vivacaine presentations, (2) FDA approval pathway history and exclusivity, and (3) competitive pricing pressure from generics of bupivacaine injection and related formulations. For an investor, the core question is whether any non-expired formulation, method-of-use, or manufacturing patents still block generic substitution for the exact dosage forms marketed as “Vivacaine.”

Because “Vivacaine” can refer to more than one marketed presentation across jurisdictions and because investment-grade analysis requires mapping the exact NDC-presentations and Orange Book listings to the corresponding patent numbers and expiration dates, a complete fundamentals dossier cannot be produced from the information provided.

What is Vivacaine and what revenue drivers matter for investors?

Core product identity. Vivacaine is marketed as a local anesthetic containing bupivacaine. As with most established local anesthetics, revenues typically depend on:

• formulary positioning in procedural settings (anesthesia, pain management, regional blocks)
• hospital purchasing contracts and group purchasing organization pricing
• supply stability and SKU availability (single-dose vs multi-dose, with or without preservatives)
• substitution risk versus branded and generic bupivacaine competitors

Primary investment drivers.

• Volume stability vs price erosion: bupivacaine is a mature molecule with extensive generic penetration in many markets.
• Lifecycle management: new concentrations, delivery formats, or combinations can shift substitution economics if protected by patents and exclusivity.
• Patent defensibility: whether any Vivacaine-specific patents remain active for the relevant NDCs.

Which bupivacaine injection forms typically compete with Vivacaine?

• bupivacaine hydrochloride injection (multiple strengths)
• preservative-free variants
• epinephrine-containing formulations (where applicable)
• regional anesthesia products and branded comparators

What patents protect Vivacaine and how many patents cover it?

Featured snippet answer: Patent protection for Vivacaine, if any, must be assessed at the presentation level using Orange Book listings tied to the specific NDC(s) for “Vivacaine” (not at the molecule level alone). Without the exact Orange Book record set and NDC mapping, patent counts and expiration dates cannot be stated accurately.

Patent types investors should check for bupivacaine brands

• Composition of matter patents (drug substance salts, polymorphs, crystalline forms where relevant)
• Formulation patents (preservative-free, pH control, stabilizers, surfactants, solvent systems)
• Method-of-use patents (indication-specific or dosing-regimen-specific claims)
• Manufacturing process patents (sterility assurance, aseptic process parameters)
• Device/combination patents (if Vivacaine is packaged or co-administered with specific delivery tech)

When does Vivacaine lose exclusivity and what are the key expiration dates?

Featured snippet answer: Exclusivity and patent loss for Vivacaine depend on the exact FDA approval(s) tied to each NDC and the listed Orange Book patents. Without the precise FDA product identifiers and corresponding patent list, a reliable exclusivity timeline cannot be constructed.

What to track in the exclusivity timeline

• regulatory exclusivity start date tied to FDA approval
• patent expiration dates (composition/formulation/process)
• any exclusivity extensions (rare for mature local anesthetic products unless a new protected formulation/indication exists)
• pediatric exclusivity add-ons (if applicable to any relevant approval)

What is the Orange Book status of Vivacaine?

A complete Orange Book status assessment requires:

• the specific FDA application/holder behind “Vivacaine”
• the list of Orange Book patents for each NDC strength/form
• whether patents are marked “F” (method-of-use) or “P” (composition/process) and the listed exclusivity codes, if any

No Orange Book patent list and NDC table can be produced from the prompt alone, so no actionable “status now” or “nearest launch date risk” can be stated.

Which companies are challenging Vivacaine with Paragraph IV ANDA filings?

A Paragraph IV analysis requires:

• the current ANDA challenger filings for the same reference listed drug and NDC presentation
• district court case numbers and dates
• settlement terms that affect launch timing

Without the Orange Book/RLD and NDC-specific ANDA litigation record, it is not possible to identify challengers, litigation posture, or generic launch risk for Vivacaine.

What generic entry risks exist for Vivacaine and when could generics launch?

Featured snippet answer: Generic entry risk hinges on whether any unexpired, NDC-linked Vivacaine patents cover the drug product as marketed. For bupivacaine, risk is often high where patents have expired for the specific strength/formulation. Timing depends on:

• patent expiration vs exclusivity expiration
• any “carve-out” waivers in settlements
• FDA approval timing for ANDAs that include paragraph IV certifications

A date-based launch scenario cannot be produced without the exact patent expiration set and any settlement-driven “first commercial marketing date” constraints.

How does Vivacaine compare with other bupivacaine brands on patent and competitive pressure?

At a high level, investors should compare:

• the number of active, presentation-relevant patents each brand has at the NDC level
• how much of the brand’s revenue is tied to most substitutable SKUs (common strengths, generic-available presentations)
• whether any brand has a differentiated formulation that remains protected

A defensible Vivacaine-vs-competitors ranking requires patent estate data per NDC and marketplace SKU mapping, which cannot be constructed from the provided input.

What formulations are protected by Vivacaine patents?

For bupivacaine brands, “protected formulation” typically means:

• preservative-free compositions
• specific pH ranges or buffer systems
• stabilizers preventing precipitation or degradation
• sterile manufacturing method claims that can block generic labeling substitutions

A formulation protection table listing patents, claim coverage, and expiration dates requires the Orange Book patent numbers and their linked dosage forms. That dataset is not present.

What method-of-use patents apply to Vivacaine dosing or indications?

Method-of-use exposure often impacts:

• labeling-controlled substitution
• whether generics must seek narrower indications or carve-outs
• litigation outcomes tied to claim construction

No Vivacaine method-of-use patent list is available in the prompt, so no indication-level risk mapping can be provided.

What patent litigation affects Vivacaine and what settlement terms matter for investors?

Settlement terms that affect valuation often include:

• launch date timing (early-entry dates)
• market withdrawal or “no-launch” covenants
• exclusivity carve-outs and NDC-level restrictions
• licensing fees or milestone payments

No case identifiers, settlement dates, or court dockets are provided, so a litigation impact analysis cannot be completed.

What is the FDA regulatory pathway for Vivacaine and how does it shape competition?

Most generic entry for established local anesthetics occurs via ANDAs referencing an established RLD. The investment implication is straightforward:

• if Vivacaine is an established product and no relevant exclusivities remain, competition tends toward rapid generic substitution
• if the specific Vivacaine presentation has recent protected reformulations, generic entry can be delayed

A pathway and approval history assessment requires the FDA review history tied to the exact Vivacaine RLD application.

How strong is the patent estate for Vivacaine?

Featured snippet answer: Patent estate strength must be scored at the presentation level with:

• number of unexpired claims
• claim scope and remaining enforceable life
• litigation/validity history (if any)
• likelihood of generic “design-around” versus labeling carve-outs

No patent estate dataset is provided, so no strength score can be stated.

Investment scenario: base, downside, and upside outcomes for Vivacaine

Base case (generic substitution continues)

• Vivacaine faces ongoing price pressure as bupivacaine generics and multi-source suppliers compete.
• Brand-specific differentiation persists only where patents or formulation exclusivity still exist.

Downside case (active patent expiry and rapid ANDA launch)

• If Vivacaine-linked patents expire near-term and no settlements delay entry, a step-change in volume and margin decline can occur upon first-to-market generic launches.

Upside case (remaining unexpired formulation/process protection)

• If specific Vivacaine SKUs remain protected longer than peers, the product can sustain pricing and share through the next formulary cycles.

Actionable requirement not met: The scenario set requires NDC-level patent expiration dates and current ANDA/Paragraph IV posture.

Commercial fundamentals investors typically model for mature local anesthetics

Even without patent dates, investors typically model:

• hospital procurement dynamics (tender cycles, GPO contracting)
• payer mix (commercial vs government purchasing)
• gross-to-net economics (rebates, administrative fees, wholesaler fees)
• inventory dynamics and supply chain risk
• competitive set and number of qualified generics

A “Vivacaine-specific” revenue model still depends on the actual marketed presentation and revenue base, which is not provided.

Key Takeaways

• Vivacaine’s investment case is determined by presentation-specific patent and Orange Book status for bupivacaine.
• Without the exact Vivacaine NDC(s), Orange Book patent list, and any Paragraph IV litigation records, an investment-grade assessment of exclusivity timelines, generic launch dates, and patent estate strength cannot be produced.
• For mature local anesthetics, the default expectation is price erosion unless a brand has remaining formulation/process protection for specific SKUs.

FAQs

1. How do I map “Vivacaine” to the correct FDA reference listed drug (RLD) for patent analysis?
2. What does an Orange Book patent code (P vs F) imply for generic substitution risk?
3. How do settlements in Paragraph IV cases typically affect first generic launch timing?
4. What labeling or NDC differences create “carve-out” opportunities for generics of bupivacaine?
5. What commercial indicators best predict loss of market share for hospital-supplied local anesthetics?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. (Accessed via FDA Orange Book database).